Eli Lilly Wins FDA Approval for Inluriyo-Verzenio Combination
Indianapolis, Indiana, September 18, 2026 Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA)...
CDK4/6 Inhibitor
Advertisement
FDA Grants Accelerated Approval to Etcamah for Breast Cancer
Silver Spring, Maryland, USA, September 4, 2026 The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
AstraZeneca Wins U.S. Approval for ETCAMAH in Breast Cancer
Cambridge, UK — September 4, 2026 AstraZeneca announced that ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor has received...
CorTec Brain Interchange Gains Second FDA Breakthrough Designation
Freiburg, Germany, August 31, 2026 Kazia Therapeutics has announced plans to expand its ongoing paxalisib clinical trial into hormone...
Kazia Expands Paxalisib Trial Into HR+ Breast Cancer
Sydney, Australia, September 1, 2026 Kazia Therapeutics has announced plans to expand its ongoing paxalisib clinical trial into hormone...
Advertisements
LeonaBio Advances Lasofoxifene Phase 3 Breast Cancer Trial
BOTHELL, Wash., Aug. 14, 2026 LeonaBio, Inc. reported continued progress in the Phase 3 ELAINE-3 clinical trial evaluating lasofoxifene...
Annexon Expands Phase 3 ARCHER II Trial in Geographic Atrophy
BRISBANE, Calif., August 12, 202 Annexon, Inc. announced the expansion of its ongoing Phase 3 ARCHER II trial evaluating...
LeonaBio Advances Lasofoxifene in Metastatic Breast Cancer
BOTHELL, Wash., August 12, 2026 LeonaBio, Inc. announced that its lead investigational therapy lasofoxifene will be featured in multiple...
Pfizer Expands IBRANCE Label with New FDA Approval for HER2+ Breast Cancer
NEW YORK, June 24, 2026 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved IBRANCE®...
AstraZeneca’s Camizestrant Extends Survival in ESR1-Mutant Breast Cancer
CHICAGO, Illinois, USA, June 2, 2026 AstraZeneca has announced compelling new results from its pivotal Phase III SERENA-6 trial,...
Advertisement
